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Abstract (275/275) 
NAFLD is a spectrum comprised of isolated steatosis, NASH, advanced fibrosis, and cirrhosis. 
The majority of NAFLD subjects do not have NASH and don’t carry a significant risk for adverse 
outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In 
Asia, a gradient of high prevalence rates to low rates are noted from urban to rural areas.  Given 
the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be 
substantial. With increasing recognition as an important liver disease, the diagnosis of NASH 
still requires a liver biopsy which is suboptimal. Although liver biopsy is the most accurate 
modality to diagnose and stage the severity of NASH, it suffers from being invasive, costly, 
associated with potential complications, and plagued with interobserver variability of individual 
pathologic features. A number of non-invasive modalities to diagnose NASH and stage liver 
fibrosis are being developed. These include predictive models (NAFLD fibrosis score) and 
serum biomarkers such as Enhanced Liver Fibrosis, (ELF). Other tests are based on radiologic 
techniques such as transient or MR elastography (MRE) which are used to estimate liver 
stiffness as a potential surrogate of hepatic fibrosis. Although a dynamic field of research, most 
of these diagnostic modalities have AUROC between 0.76 to 0.90% with MRE having the best 
predictive performance. In summary, developing accurate, safe and easily accessible non-
invasive modalities to accurately diagnose and monitor NASH and associated fibrosis is of 
utmost importance in clinical practice and clinical research. These tests are not only important to 
risk stratify subjects at the greatest risk for progressive liver disease but to serve as appropriate 
surrogate endpoints for therapeutic clinical trials of NASH. 
Key words: predictive models, noninvasive, biomarkers, imaging  
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Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, 
worldwide. [1] Based on a recent meta-analysis, 25% of the general adult population in the 
world are potentially affected by NAFLD. [1] Although NAFLD was initially reported to be more 
prevalent among Hispanics, it is now increasingly reported from all regions of the world. [1]. 
Furthermore, the prevalence of NAFLD in children is also high and estimated to be around 10% 
[2,3,4].  
Data on the incidence of NAFLD are quite sparse.  Of the available data, the estimated NAFLD 
incidence is reported to be between 28 to 52/1000 person-years. [1]. However, these incidence 
rates are probably underestimations, given the rising incidence of obesity and diabetes, two of 
the primary associated risk factors for NAFLD.  
 The long-term outcome of the spectrum of NAFLD has been described in observational studies. 
In fact, data suggest that most patients with NAFLD die primarily of cardiovascular 
complications [4-6]. Nevertheless, there are subgroups of NAFLD patients, primarily those with 
histologic NASH or significant hepatic fibrosis, who are at risk for developing advanced liver 
disease, hepatocellular carcinoma (HCC), excess liver-mortality, or become candidates for liver 
transplantation (1, 7-12). In fact, more recent studies have suggested that stage of fibrosis, 
independent of any other histologic feature, predicts mortality in NAFLD 
In addition to the clinical burden, NASH places significant burden on patient reported outcomes 
(PROs) and the economy [13-18]. A recent Decision Analytic Markov Model estimated 
tremendous economic burden of NAFLD and NASH to the US and European economies. [19] 
These data provide strong evidence that the progressive form of NAFLD or NASH, especially 
those with significant fibrosis pose tremendous clinical, PRO, and economic burden to 
individuals and the society. [14-20]  
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This manuscript is the summary of data presented at a recent AASLD Emerging Trend 
Conference on NASH on the state of diagnostic modalities for NASH and fibrosis.  
The Initial Steps in the Diagnosis of NAFLD: 
 
Prior to the initiation of exhaustive diagnostic tests for NAFLD, it is important for health care 
providers to exclude other etiologies for steatosis and coexisting common causes of chronic 
liver disease. Specifically, excessive alcohol consumption and other exogenous factors (ex, 
steatogenic medications) must be excluded. [1,3,21] Furthermore, in patients with persistently 
high serum ferritin, and increased iron saturation, especially in the context of homozygote or 
heterozygote C282Y HFE mutation, iron overload must be considered. Although low titer 
autoimmune markers can be frequently seen in patients with NAFLD, autoimmune liver disease 
should be ruled out in patients with high serum titers of autoantibodies in association with other 
features such as high serum globulins.   [1, 3, 21] 
Once other causes of steatosis have been ruled out, NAFLD should be considered. In this 
context, presence of commonly associated comorbidities such as obesity, dyslipidemia, insulin 
resistance or diabetes, hypothyroidism, polycystic ovary syndrome, and sleep apnea should be 
determined. [3, 21]  
 
Role of Histopathology in the Clinical Research and Management of Patients with NAFLD  
 
The liver biopsy is the definitive technique for the diagnosis and classification of NAFLD in 
which the role of histopathology is to establish a diagnosis, characterize the liver lesions, and 
correlate the lesions with potential clinical outcomes in the context of the natural history of the 
disease. (7, 23-30) Historically, the terminology and concepts of the histopathologic features of 
NAFLD were derived from alcoholic liver disease. Thus, alcoholic fatty liver (AFL) is analogous 
to simple steatosis (NAFL), alcoholic hepatitis to nonalcoholic steatohepatitis (NASH), and 
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alcoholic cirrhosis to the cirrhotic stage of NAFLD. [23] Although there may be differences in 
degree, the features are sufficiently similar to preclude an etiologic diagnosis based on histology 
alone. Therefore, the characteristic histopathologic features which are investigated when 
diagnosing AFL or NAFL include: 1). Fat – hepatocellular triglyceride accumulation, 2). 
Hepatocellular injury in the centrilobular location which is most severe in the acinar zone, 3). 
Cytoskeletal damage shown as hepatocellular ballooning with or without Mallory-Denk bodies, 
4). Parenchymal inflammation where lymphocytes and macrophages predominate, though 
neutrophils may be present in severe cases, and 5). Perisinusoidal fibrosis seen as collagen 
deposition in the space of Disse. (Figure 1) 
As an aid to help characterize these lesions and allow for statistical analysis in clinical trials, the 
pathologists of the National Institute of Health NASH Committee (NIH NASH CRN) devised a 
grading system called the NAFLD Activity Score (NAS). [29] (Table 1) After studying the inter- 
and intra-observer variability of a variety of histologic features, the features with the greatest 
reproducibility (severity of steatosis, hepatocellular ballooning, and lobular inflammation) were 
chosen to formulate the NAS score. The NAS system then assigns a numerical grade to each 
feature such that the severity of steatosis is graded from zero to three (0 to 3), hepatocellular 
ballooning is graded from zero to two (0 to 2), and lobular inflammation is graded from zero to 
three (0 to 3). The NAS score is the unweighted sum of these three numbers with a range from 
zero to eight (0 to 8).  Improvement in histologic severity is accompanied by a decrease in the 
NAS.  [29] More recently, a refinement of this scoring system, called the SAF Score, has been 
proposed. Although on the face of it SAF appears to be a very similar system, the SAF Score 
separates degree of steatosis (S) from grade of necroinflammatory activity (A) and so may 
provide greater granularity in terms of disease activity and help distinguish steatosis from 
NASH. [30] 
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However, the histologic feature with the greatest reproducibility is fibrosis, a feature which is not 
part of the NAS score because fibrosis is considered a sign of the stage of disease rather than a 
grade of injury.  Fibrosis staging is, therefore, scored separately.  Accordingly, in the NASH 
CRN system fibrosis stage 0 = no fibrosis; stage 1 = centrilobular pericellular fibrosis (or 
periportal fibrosis in children); stage 2 = centrilobular and periportal fibrosis; stage 3 = bridging 
fibrosis; and stage 4 = cirrhosis. [8,22,30] (Figure 1) 
As a result of this histologic work done on NAFLD, the natural history of the various lesions 
associated with NAFLD are gradually being elucidated. For example, fatty liver, alone or with 
some lobular inflammation but without evidence of cytoskeletal damage (ballooning or Mallory-
Denk bodies) or fibrosis, has long been considered non-progressive liver disease; however, 
recent follow-up studies, have found that some patients do, in fact,  eventually develop fibrosis 
and even cirrhosis. (30) Another example is NASH with ballooning ± Mallory-Denk bodies, 
which has long been thought to be the progressive form of NAFLD; however, recent long -term 
follow-up studies have found that the single histologic feature that predicted mortality was not 
NASH but fibrosis in the liver biopsy. [8,22,30] Furthermore, studies of NAFLD patients with 
paired biopsies found that spontaneous regression of fibrosis may be an important feature in 
NASH, both in the long-term and short-term. [22,25]  
With these findings in mind, a collaborative effort with NIH NASH CRN was undertaken where 
two scoring systems were developed to grade the level of liver injury associated with NAFLD 
(NAS) and stage the level of disease associated with NAFLD- fibrosis score.  As such, the use 
of histology in diagnosing NAFLD has allowed a more in-depth understanding of the natural 
history of the various NAFLD histologic lesions, but more information is still needed on the 
mechanisms of fibrosis progression and development of cirrhosis in patients with NAFLD.   
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The Role of Radiologic Modalities for Diagnosing, Staging and Monitoring NASH  
Although, liver biopsy is the gold standard to diagnose NASH and assess the stage of fibrosis in 
patients with NAFLD, its many limitations (cost, sampling error, complications leading to 
morbidity, and though rare, death) prohibit its routine use. [11, 25, 26] However, when a clinician 
sees a patient for the first time with suspected NAFLD, he/she would like to know the following: 
1) Whether the patient has NAFLD, 2) Whether the patient is likely to have underlying NASH, 3) 
Whether the patient has any fibrosis, 4) Whether the patient has any advanced fibrosis?  As a 
result, there is an urgent need for an accurate non-invasive diagnostic modality for the diagnosis 
and staging of NAFLD and NASH. [31] 
In the context of NAFLD, the first diagnostic challenge is to accurately show the presence of fat 
in the liver. Currently, 20%-33% is considered a reliable level at which steatosis is detected by 
conventional means; however, the presence of fat greater than 5% to 10% is considered 
abnormal. [22, 31-36] 
 Fat is thought to have its own chemical signature which can be detected directly by magnetic 
resonance spectroscopy (MRS). When performed properly, MRS quantifies the proton density 
fat fraction (PDFF), a standardized measure of liver tissue [TG]. [34] However, the limitations of 
MRS include: restricted availability, need for expertise in protocol prescription, data collection 
and spectral analysis is required. Furthermore, MRS is not available on routine scanners. 
Therefore, now, MR Imaging based methods have been developed using MRI-PDFF to quantify 
liver fat without needing spectroscopy coils using routinely available clinical MRI scanners (33-
40). MRI- Proton density fat fraction (PDFF) addresses confounding factors and is not affected 
by scanner field strength, patient factors (age, sex, BMI, etiology of liver disease), and 
concomitant liver abnormalities such as iron overload or necroinflammation. [34,41-43]  
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In contrast, fibrosis has no molecular signature that can be detected by current imaging 
techniques so all imaging tests for fibrosis attempt to detect fibrosis indirectly using proposed 
biomarkers which include: stiffness, diffusion, perfusion, metabolites, and image texture. 
However, the leading biomarker is liver “stiffness” (or “elasticity”) and its family of related 
parameters. [34] The rationale for using “stiffness” or “elasticity” is that the collagen deposition 
associated with fibrosis imparts parenchymal rigidity which on imaging tests is considered as 
assessing “stiffness” or “elastography”. (34-43) 
The most accurate noninvasive methods to assess the stiffness of the liver and to dichotomize 
the patient into advanced versus non-advanced fibrosis include transient elastography (TE), 
magnetic resonance elastography (MRE), and emerging techniques such as shear wave 
elastography and acoustic radial force imaging [38,44-46] (Figure 2) 
Transient elastography has been shown to have an AUC of 0.83 for advanced fibrosis when 
compared to blood tests. Overall, TE has a 90% negative predictive value (NPV), a sensitivity of 
88%, a positive predictive value (PPV) of <65%, and places the fewest patients (43.6%) in what 
is considered “the grey zone” compared to blood tests. Furthermore, TE has been shown to also 
have prognostic ability. Since TE has diagnostic accuracies of 80.8%, it is thus able to 
categorize patients into subgroups found to be have different prognoses. [47]  
Using a “stiffness” cutoff of 3.63 kPa, MRE sensitivity has a sensitivity of 0.86 (95% confidence 
interval [CI]: 0.65-0.97), a specificity of 0.91 (95% CI: 0.83-0.96), a PPV of 0.68 (95% CI: 0.48-
0.84), and a NPV of 0.97 (95% CI: 0.91-0.99) with an area under the curve (AUC) of advanced 
of 0.924 for diagnosing advanced fibrosis.) [39] In addition, the use of 3D MRE has shown that 
at 40Hz and a “stiffness” cutoff of 2.43 an AUC of 0.962 for diagnosing advanced fibrosis. [46] In 
fact, in a recent study comparing ARFI based versus MRE-based NAFLD fibrosis assessment, 
MRE was significantly better. [45] Further, MRE was significantly better than TE when 
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diagnosing cirrhosis.[48] There are several caveats that must be addressed before using MRE. 
These caveats include: the cost of the procedure, the patient size, the presence of 
claustrophobia or the presence of metal implants. (46,48) 
Although TE or other ultrasound-based tests are more accessible and easier to use, they are 
limited when used in patients with obesity, ascites, or acute inflammation. [34] However, even 
though, the 2D and 3D MRE is able to overcome all these issues except for iron overload or 
acute inflammation, it is limited by the having restricted accessibility at many centers especially 
worldwide and the required expertise needed to obtain adequate results in the setting of 3D 
MRE. So, as of now, accurate imaging is a trade-off between specificity, accessibility, and ease 
of use such that as specificity goes up accessibility and ease go down. It is also reasonable to 
use ultrasound based tests in non-obese individuals and consider using MRE in individuals with 
obesity especially morbid obesity. [34,38,45] Further research is needed to quantify the exact 
trade off that occurs when one imaging technique is traded off for the other. 
Noninvasive Biomarkers in NASH  
In addition to the non-invasive tests based on the imaging modalities, there is an attempt to 
define non-invasive biomarkers using predictive models or serum biomarkers. These non-
invasive markers include those that are based on alanine aminotransferase levels, those that 
include components of metabolic syndrome, measuring circulating keratin18 fragment levels as 
well as tests based on soluble markers such as Fibrometer, microRNA panels, and lipidomic 
panels.  [49-61] 
Using these non-invasive tests to diagnose for NASH, current studies have found that the 
frequency of NASH in individuals with normal ALT (<35 U/L) was 11% whereas the frequency 
was 29% in those with elevated ALT (≥35 U/L) and if the ALT was two times the upper limit of 
normal (>70 U/L), predicting NASH was found to have a 50% sensitivity and 61% specificity for 
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NASH. [49] Another study found that individuals with NAFLD can have normal ALT levels as the 
disease progresses. [62] 
Feldstein et al., in their seminal work, found that circulating levels of cytokeratin-18 (CK-18) 
fragments were predictors of NASH in patients with NAFLD. [53] Since the release of their 
observations, there has been intense investigations which have unequivocally found that 
increased circulating levels of CK-18 fragments are associated with NASH. [54,55] However, at 
the same time, there are a number of issues with this diagnostic method (lack of a commercially 
available clinical test, poor reproducibility with limited sensitivity/specificity at the individual 
patient level [51] and a lack of a clear cut-off point) which limit its clinical utility at the present 
time. [62]  
Others have looked into combining these different measures to diagnose NASH. Loomba and 
colleagues examined the efficacy of a panel of eicasanoids in the detection of NASH using a 
lipidomics based approach and showed excellent diagnostic accuracy ranging between 0.9-1.0. 
[63]. These data need to be confirmed in larger, multicenter studies.  
The NASH Test combines demographic characteristics (age, gender, and BMI), serum 
parameters (aminotransferases and lipids), and alpha-2 macroglobulin, ApoA1, and 
haptoglobin. The NASH Test sensitivity is 33% with a specificity of 94% indicating it has a good 
negative predictive value (NPV) for NASH of 81%. [54]. Another combined test, The NASH 
Diagnostics Panel, which uses the presence of CK-18 fragments, adiponectin, and resistin 
initially performed well but in a larger study was not found to be as effective. [55] The NAFLD 
Diagnostic Panel, used CK-18 fragments in combination with the presence of type II diabetes 
mellitus, triglycerides, and gender, but it did not perform any better than the NASH Diagnostics 
Panel [56].  
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On the other hand, the OXNASH score, which uses AST, age, BMI and a ratio of 13-hydroxy-
octadecadienoic acid (13-HODE) to linoleic acid (LA), correlates with histologic features of 
NASH and provides AUC’s of 0.730 [95% CI (0.637, 0.823)] for inflammation; followed by 
ballooning of 0.723 [95% CI (0.630, 0.816)], steatosis 0.705 [95% CI (0.570, 0.840)]; and 
fibrosis 0.673 [95% CI (0.577, 0.770) [57, 58] . The Hepascore, derived from age, gender, 
bilirubin, gamma glutamytransferase [GGT], hyaluronic acid, a-2 macroglobulin, when compared 
to a simple non-invasive score [BARD Index (BMI, AST, ALT, Diabetes)] performed reasonably 
well in identifying fibrosis F2-F4 with AUC’s of 0.73 to 0.91 with more accuracy noted for 
patients with a fibrotic stage of 4. [47,59] The Fibro meter NAFLD (Age, weight, fasting 
glucose,AST, ALT, ferritin and platelet count) performs reasonably well in identifying mild to 
moderate fibrosis. The positive predictive value (PPV) for correctly identifying F=1 was 84.9%  
for the Fibro meter NAFLD with a negative predictive value (NPV) of 66.7% and a diagnostic 
accuracy of 80%. The PPV for F=3 was found to be 74.5%with a NPV of 86.2 and a diagnostic 
accuracy of 82.1%. [64] Several prognostic scores (Palekar score, Shimada index, Nice model, 
Gholam’s model), have also been developed with all performing somewhat similarly with AUC 
ranging from 0.76 to 0.90 [60,61]. 
 
Metabolic syndrome is another commonly used index to identify individuals with NAFLD at risk 
for NASH. Several studies have found a significant relationship between the increasing number 
of metabolic syndrome components and the likelihood of NASH in patients with NASH. (65-67) 
Yet, what has not been explored is the combination of metabolic syndrome, levels of ALT and 
age to predict NASH in NAFLD leaving another area of further exploration.   
With these continuing challenges in correctly diagnosing NASH, the NAFLD scientific 
community needs to reevaluate the need for predicting NASH in patients with NAFLD. Should 
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we instead focus on NASH with stage ≥2 fibrosis as it is the sub-phenotype that is primarily 
targeted in Phase 2B and Phase 3 clinical trials?  
Serum Fibrosis Markers in Non-alcoholic Steatohepatitis  
Since stage of fibrosis is the most important predictor of outcome [8,10, 68] a great deal of effort 
has focused on determining presence of fibrosis. [8] In this context, NAFLD biomarkers can 
target domains that can be defined as the following: 1) diagnostic markers, reflecting current 
stage of fibrosis; 2) prognostic markers, stratifying individuals by fibrosis progression risk, 
discriminating fast vs. slow progressors and/or predict long-term outcomes and hard endpoints; 
and 3) monitoring markers, that may be used to track disease progression or treatment 
response. Such biomarkers should be at one of four qualification levels: 1) exploration (early-
phase experimental biomarkers), 2) demonstration (“probable valid” biomarkers), 3) 
characterization (“known valid” biomarkers), and 4) surrogacy (registerable “surrogate 
endpoint”). [69-82] Although there has been some progress in biomarker development for 
detection of advanced fibrosis, existing biomarkers are generally at the first two qualification 
levels and need further independent validation.  
 
Serological markers for the evaluation of liver fibrosis may be divided into ‘indirect’ markers (that 
reflect alterations in hepatic function but not collagen turnover, e.g. ALT, AST and platelet 
levels) and ‘direct’ markers (that directly measure aspects of extracellular matrix (ECM) 
deposition and/or turnover). [69,71] Furthermore, novel kinetic biomarkers using deutered water 
based approaches are emerging to assess dynamic changes in the fractional synthesis rate of 
collagen turn over in the liver in patients with NAFLD. [83]  
Indirect Markers and ‘Simple Panels’ 
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Significant hepatic fibrosis can lead to hepatocellular dysfunction and portal hypertension, which 
are reflected by changes in standard biochemical and haematological parameters. These tests, 
alone or combined as ‘simple panels’, are potentially attractive clinical tools as they are 
inexpensive and many indices are already routinely measured in patients with liver disease. [70] 
The results of a head-to-head comparison in a large cohort with biopsy-proven NAFLD patients 
have been published. In general, simple panels have a relatively robust NPV so they can 
reliably exclude advanced fibrosis but have poor PPV (ranging from 27-79%). [71] Using such 
tests may help to mitigate the healthcare burden such a large ‘at risk’ population places on 
resources by not allowing those considered to have ‘low-risk’ scores to undergo further 
investigation. As liver fibrosis progress towards advanced fibrosis/cirrhosis serum ALT levels 
tend to fall whereas AST levels remains stable or increases, leading to an increase in the 
AST/ALT ratio. This phenomenon is exploited as a component of many of the simple panels. 
The NAFLD Fibrosis Score (NFS) is calculated using six routinely measured parameters found 
to be independently associated with advanced fibrosis on multivariate analysis. [62] By applying 
a low cut-off (<-1.455), advanced fibrosis can be excluded with high accuracy (NPV 93%) whilst 
a high cut-off threshold (>0.676) offers accurate detection of advanced fibrosis (PPV 90%). [62] 
Use of this score has been suggested to reduce the need for liver biopsy by ~75%. Despite 
extensive external validation, NFS is not as robust in predicting advanced fibrosis in NAFLD. 
Nevertheless, NFS can accurately exclude advanced fibrosis in NAFLD and is clinically useful.  
The FIB4 Score is one of the best performing simple non-invasive tests for advanced fibrosis in 
NAFLD. A score of <1.3 has a 90% NPV for stage 3-4 fibrosis, whilst a score of >2.67 has an 
80% PPV with only a quarter of the cohort being unclassified 1.3 or above 2.67.  [73] Other 
studies have also found that the FIB-4 score narrowly out performs other simple non-invasive 
tests in predicting advanced fibrosis. [71] The specificity for advanced fibrosis using the FIB-4 
and NFS declines with age, becoming unacceptably low in patients aged over 65-years; 
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however, age-adjusted lower cut-offs (NFS <0.12 and FIB4 <2) have been derived that maintain 
the high NPV and so help to exclude advanced fibrosis in those aged ≥65-years. [74] It is also 
important to note that these scores may not be helpful in the younger age group and perform 
poorly with relatively low AUC. In this context, the exact cut off threshold and validity of these 
non-invasive tests in clinical setting require further external validation before its full clinical use 
can be recommended. [75-79]  
Direct Markers: Collagen Turnover 
When the severity of ongoing liver injury exceeds that of hepatic regeneration, hepatocytes are 
replaced by an extra cellular matrix (ECM) composed of collagens (I, III, and IV), fibronectin, 
undulin, elastin, laminin, hyaluronan, and proteoglycans 3. Candidate biomarkers derived from 
these processes are appealing targets and are currently an area of active investigation. [75,76]   
One such biomarker is hyaluronic acid (HA). HA production is increased when collagen 
synthesis is accelerated so this is a marker of increased ECM production. Similarly, liver fibrosis 
results in the deposition of collagen and release of pro-peptides, predominantly Pro-Collagen III 
(PIIINP). The terminal peptide of PIIINP correlates with the NAFLD activity score (NAS), and its 
constituent components (P<0.001) where a threshold of 6.6 ng/mL provides a NPV for 
advanced fibrosis of 95%-97% and 100% for cirrhosis. [75] The Enhanced Liver Fibrosis (ELF®) 
test is a commercial panel of markers focusing on matrix turnover comprised of tissue inhibitors: 
matrix metalloproteinase 1 (TIMP 1), HA, and aminoterminal peptide of pro-collagen III (P3NP). 
[76,80] When compared with the NAFLD Fibrosis Score this test performed only marginally 
better for severe fibrosis (AUROC 0.93 vs 0.89) and moderate fibrosis (AUROC 0.90 vs 0.86), 
but combining the two modalities enhanced efficacy (AUROC 0.98 for severe fibrosis and 0.93 
for moderate fibrosis). [81]  Fibrotest® is a commercial panel, with a reported AUROC of 0.75-
0.86 for F2-F4 and 0.81-0.92 for F3-F4.[81] Other commercial assays currently in development 
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with promising preliminary results detect pathologically modified proteins generated by specific 
proteases such as the specific collagen fragments of Pro-C3 and Pro-C6 using proprietary 
Protein Fingerprint™ ELISA assays. [82]  
Other Promising Experimental Markers: Genetics/Epigenetics, Metabolomics, and 
Lipidomics: 
Inter-patient variation in NAFLD progression risk is, at least in part, determined by genetic 
modifiers that influence individual response to environmental (diet, lifestyle) factors. [22] 
Mounting evidence indicates that epigenetic factors such as differential DNA methylation and 
circulating cell-free DNA methylation signatures in plasma, may potentially stratify patients with 
NAFLD into mild versus severe fibrosis. [83,84] MicroRNA (miRNA) is another genetic marker 
that appears to be relatively stable and can be detected in plasma following release from injured 
tissue and may serve as another disease biomarker. [85-87] These modalities remain highly 
experimental however and require further validation.  
Summary: 
Over the last forty years, NAFLD has evolved from an unrecognized entity to a heterogeneous 
collection of overlapping liver diseases with a common phenotype of having hepatic steatosis. 
Although NAFLD is quite common, affecting approximately 25% of the world’s adult population, 
it is increasingly clear that subjects with NASH and especially those with significant fibrosis are 
at the greatest risks for excess mortality and adverse clinical outcomes as well as impairment of 
PRO and significant economic burden.  
Despite the growing recognition of this important burden, there are significant challenges to 
accurately and non-invasively diagnose the progressive form of NAFLD. Although liver biopsy is 
considered the current imperfect “gold” standard for diagnosing NASH and staging fibrosis, it is 
an invasive procedure with some variability in assessment of the key features of NASH.    
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Therefore, a number of serum markers, radiographic modalities, and noninvasive predictive 
algorithms have been or are currently undergoing investigation.  To date, most of these 
modalities suffer from suboptimal performance. However, MRI-PDFF seems to be the most 
accurate modality for detecting hepatic fat while MRE seems to be the most accurate test for 
staging liver disease. Thus, a combination of MRI-PDFF and MRE may provide a relatively 
accurate method to risk stratify subjects with NAFLD. But, availability and cost of these 
modalities presents a major challenge to most clinical practices.  
As a result of the limitations of the non- invasive tests and the radiographic imaging, the 
regulatory authorities [Federal Drug Administration (FDA) and European Medical Agency 
(EMA)] now require histologic endpoints for approval of drugs and diagnostic modalities. As 
such, until non-invasive measures are perfected and robustly validated the diagnosis of NAFLD 
may continue to be underestimated and the development of therapeutic options may be 
hindered. 
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Figure Legends: 
Figure 1.  Stages of fibrosis in NAFLD according to the NASH CRN staging system (Masson 
trichrome stains).  Collagen is blue with this method. 
Stage 1 (left) – Centrilobular perisinusoidal fibrosis.  Blue stained collagen fibers outline the 
sinusoids surrounding the central vein in the center of the field. 
Stage 2 (left middle) – Centrilobular perisinusoidal fibrosis and periportal fibrosis.  Delicate 
collagen fibers are deposited around the sinusoids in the upper part of the field while denser 
collagen expands the portal tract in the lower part of the field. 
Stage 3 (right middle) – Bridging fibrosis.  A vascularized septum of fibrous tissue transects the 
hepatic parenchyma, 
Stage 4 (right) – Cirrhosis.  Nodules of hepatocytes are surrounded by variable-size fibrous 
septa. 
Figure 2: Novel 3-D MRE and Diagnosis of NASH and Advanced Fibrosis 
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Table 1.  Histologic features of NASH CRN NAFLD Activity Score (NAS) and fibrosis 
staging (27) 
 
Feature  Definition Score or Code 
Steatosis Grade  Low- to medium-power  
  evaluation of parenchymal  
  involvement by steatosis) 
   <5%   0  
   5%-33%   1  
   33%-66%   2  
   >66%   3  
Lobular inflammation  Overall assessment of all  
  inflammatory foci per 200X field 
   No foci   0  
   <2 foci per 200 field   1  
   2-4 foci per 200 field   2  
   >4 foci per 200 field   3  
Ballooning* 
   None   0  
   Few (or borderline) balloon cells   1 
   Many cells/prominent ballooning   2  
NAFLD Activity Score Sum of Steatosis + Lobular Inflammation     0 to 8 
   + Ballooning 
 
Fibrosis Stage 
  None   0  
  Perisinusoidal or periportal  1 
   Mild, zone 3, perisinusoidal   1A  
   Moderate, zone 3, perisinusoidal   1B  
   Portal/periportal   1C  
  Perisinusoidal and portal/periportal   2 
  Bridging fibrosis   3  
  Cirrhosis   4  
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